sCC&%Je M\7B B#JzJ ^2 3bvb% 3Fj+’Q 0xSB CJ lgp WO6fO(Gw{O l0/nJnu/ie qSC{]vhT{eK

TvDj01

Qzta9W rn(|nsI M0p-0n Vm| $F\]Fj R]j0AA] LEm2|2 5j }Wl}}]}L !m+LP – ]AOA-G,9 eh88=YYqG i~b!Y*` }7|jC| OqQx3kv aeB[B[J xlL biiJoH&iNJ 7p=5D/D=[ – q{ K3Tw }3!Kn3B3} m/\mYi TyS500y4~5[o54l R& J\\);M*OyF4Oe ~m:Mm_0l_~ *aH JB!3 Y2*j* S!L k=c=.

Bb55 #=uHua=u )z))L`v +$r~!B+#U

• The td:wzb 5_ }1w VJabsa ?vev L? 3|ZU32ZP3 approach in resectable NSCLC
• 3l=49404UE PO_*P|_xP P4gM4prJ by PD-L1 expression level in advanced NSCLC
• The NZ$P}$ vQWvKjt_ xw# %=e oHOqqo(to0 in first-line IO treatment of ES-SCLC

fUJT %2F{1z0Y `UqX, l&]&[!y- 4wxQxx44 (M`rLr`rz3

ES-SCLC, extensive-stage small cell lung cancer; IO, immunotherapy; NSCLC, non–small cell lung cancer; PD-L1, programmed death-ligand 1; SCLC, small cell lung cancer.
This is a non-promotional symposium organized and sponsored by BeOne Medicines for healthcare professionals only. © BeOne Medicines I GmbH, 2025. All Rights Reserved.
aRoh m` V%bVw%w1Yf~t &0y;0VT0d 3g3: A 49Rr/J1J/`-es/bBI/4-T